Researchers recently evaluated the 10-meter timed walk as a reliable tool for tracking the progression of human T-cell leukemia virus type 1-associated myelopathy (HAM/TSP). This chronic neuroinflammatory condition often leads to debilitating walking issues. However, limited data existed regarding the natural progression of gait over a decade. Consequently, clinicians required more robust longitudinal markers to measure treatment success and functional decline in these rare patients.

Monitoring Gait with the 10-meter timed walk

The Japanese HAM-net registry analysis included 142 patients followed for 10 years. Initially, the geometric mean time for the 10-meter timed walk was 12.6 seconds. By the tenth year, this figure rose significantly to 16.3 seconds, reflecting a 42.1% increase. Furthermore, the test results correlated strongly with established motor disability scores like the Osame's Motor Disability Score (OMDS). Therefore, the study confirms that gait speed is a sensitive indicator of long-term disease worsening.

Moreover, the research highlighted significant links between walking speed and activities of daily living. Specifically, the Health Assessment Questionnaire (HAQ) scores showed a positive correlation with timed walk results. This suggests that even subtle changes in gait speed impact a patient's overall quality of life. Additionally, clinicians can use these metrics to differentiate between disease stages in routine practice.

How does the 10-meter timed walk help in HAM/TSP management?

The 10-meter timed walk provides a quantitative measure of gait speed, which correlates with long-term motor disability and functional independence. It allows clinicians to monitor disease progression and evaluate the efficacy of therapeutic interventions objectively.

Are there other scores used alongside the 10mTW?

Yes, clinicians often use the Osame's Motor Disability Score (OMDS) and the Health Assessment Questionnaire (HAQ) to provide a comprehensive view of the patient's neurological status and daily functioning.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional consultation is required for specific diagnosis or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Marubayashi F et al. Use of the 10-meter timed walk for monitoring long-term gait progression in human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis: a 10-year analysis from the Japanese HAM-net registry. Orphanet J Rare Dis. 2026 May 25. doi: 10.1186/s13023-026-04399-y. PMID: 42185916.

Adonis A, Taylor GP. Assessing walking ability in people with HTLV-1-associated myelopathy using the 10 meter timed walk and the 6 minute walk test. PLoS One. 2016;11(6):e0157132.

Araujo A, et al. Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2021. Neurology Clinical Practice. 2021;11(1):49-56.